RT Journal Article
SR Electronic
A1 Shuman, Jill
T1 Safety and Efficacy of Enzalutamide in Men with Metastatic Prostate Cancer: The PREVAIL Trial
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 14
SP 20
OP 21
DO 10.1177/155989771414013
UL http://mdc.sagepub.com/content/14/14/20.2.abstract
AB This article presents data from A Safety and Efficacy Study of Oral MDV 3100 [enzalutamide] in Chemotherapy-Naïve Patients With Progressive Metastatic Prostate Cancer [PREVAIL; NCT01212991; Beer TM et al. N Engl J Med 2014]. Enzalutamide, an androgen receptor inhibitor, has been shown to improve overall survival (OS) and radiographic progression-free survival (rPFS) in men with metastatic castrate-resistant prostate cancer (mCRPC) who had received docetaxel therapy [Scher H et al. N Engl J Med 2012]. PREVAIL researchers examined whether enzalutamide could prolong OS and rPFS in men with mCRPC who had progressed on androgen deprivation therapy.